Temporal Changes in Post-Discharge Risk among Patients Hospitalized for Heart Failure: An EVEREST Story
Abstract: Studies have shown patients suffering from a heart failure hospitalization are at higher risk for an adverse event in the first 90 days post-discharge. This claim has led to the conclusion of a vulnerable phase for these patients. The vulnerable phase hypothesis has ties to research, health care, and quality of care initiatives. However, as the case with chronic diseases, shouldn't risk continue to increase over time? A post-hoc analysis of the Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan (EVEREST) trial, may show just that.